Neuronetics, Inc.

Neuronetics develops and commercializes the NeuroStar Advanced Therapy System, an office-based treatment platform for patients with major depressive disorder. The system uses transcranial magnetic stimulation to deliver MRI-strength magnetic pulses designed to stimulate specific brain regions associated with mood regulation. The treatment is non-invasive and non-systemic, administered in an outpatient clinical setting without requiring systemic medication. The company targets psychiatrists as its primary customer base for system sales and ongoing patient treatments.

The NeuroStar Advanced Therapy System represents the company's core revenue stream. The business model centers on direct sales of equipment to psychiatric practices combined with ongoing patient treatment sessions conducted at clinical facilities using the installed systems. The company operates with a dedicated sales and customer support organization focused on psychiatry specialists.

Neuronetics operates with approximately 716 full-time employees and maintains its headquarters in Malvern, Pennsylvania. The company holds a market capitalization of $0.1 billion and conducts business across the United States and select international markets. Founded in 2001 and incorporated in Delaware, the company trades on Nasdaq under the ticker STIM.